Friday Satellite Symposia
Lymphoid Leukemias, ALL, Combination therapy, Drug development, Education, Diseases, Therapy sequence, Treatment Considerations, Lymphoid Malignancies, Adverse Events, Measurable Residual Disease
Room 30
(San Diego Convention Center)
Chair:
Elias Jabbour, MD, The University of Texas MD Anderson Cancer Center
Disclosures:
Jabbour: AbbVie, Adaptive Biotechnologies, Amgen, Astellas Pharma, BMS, Genentech, Incyte, Pfizer, Takeda: Consultancy; AbbVie, Adaptive Biotechnologies, Amgen, Ascentage Pharma Group, Pfizer, Takeda: Research Funding.
Speakers:
Hagop M. Kantarjian, MD, The University of Texas MD Anderson Cancer Center
,
Aaron C. Logan, MD, PhD, University of California San Francisco
,
Rob Pieters, MD, PhD, Princess Máxima Center for Pediatric Oncology
and
Claire Roddie, MD, PhD, University College London Hospitals
Disclosures:
Kantarjian: AbbVie, Amgen, Ascentage, Ipsen Biopharmaceuticals, KAHR Medical, Novartis, Pfizer, Shenzhen Target Rx, Stemline,Takeda: Consultancy, Honoraria. Logan: Pfizer: Consultancy; Talaris: Research Funding; Pharmacyclics: Research Funding; Kite: Consultancy; Amgen: Consultancy, Research Funding; Kadmon/Sanofi: Research Funding; Astellas Pharma: Research Funding; Autolus: Research Funding; Bristol Myers Squibb: Consultancy; Actinium: Consultancy; AbbVie: Consultancy; Kite/Gilead: Research Funding; Sanofi: Consultancy; Takeda: Consultancy. Pieters: Erytech Pharma, Inc: Consultancy; Servier Pharmaceuitcals, Inc.: Consultancy, Research Funding, Speakers Bureau; Pfizer: Research Funding; Celgene Corp.: Research Funding; Amgen: Research Funding, Speakers Bureau; Jazz Pharmaceuticals, Inc.: Consultancy, Speakers Bureau; Novartis Pharmaceuticals Corp.: Consultancy. Roddie: Autolus Tx: Consultancy; Kite Gilead: Consultancy, Speakers Bureau; novartis: Honoraria; Johnson&Johnson: Honoraria; Bristol Myers: Honoraria.
On Demand program will be available here December 7, 2024.
Access Program Here
The rapid pace and sheer volume of basic science and therapeutic developments that continue to emerge in the field of ALL create practice and/or educational gaps, particularly for hematology-oncologists and oncology nurses who strive to deliver the best possible care to patients. This Medical Crossfire® will provide an ideal format for the leukemia care team to participate in an open exchange of ideas and viewpoints fostered by a case-based agenda allowing them to review patient scenarios, reflect on how they might handle particular cases, integrate relevant evidence into real-world practice, and compare their patient care approaches with those of experts and peers. Faculty leading discussion of common clinical scenarios and solutions will discuss methods to best integrate the latest therapies into ALL treatment paradigms, address barriers to optimized integration of these novel agents, as well provide best practices for the management of adverse events.
denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.